RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

Latest press releases

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI is proud to have provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. The results of the study, recently published in the British Journal of Ophthalmology, demonstrate that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis.

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI is a leader in clinical and imaging data management software and advanced analytics for Ophthalmology. The company’s platform technology and AI improve workflows in research, clinical studies and bring precision medicine applications to pharma, clinical research organizations (CROs) and clinicians.

RetinAI Expands Operations to Set Up a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

RetinAI, a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.

RetinAI will attend EURETINA 2022 from September 1st to 4th in Hamburg

RetinAI will attend the 22nd EURETINA Congress, from September 1st to 4th, at the CCH (Congress Centre Hamburg) in Hamburg, Germany. EURETINA 2022 attendees will get first-hand insights on the company’s two new products: Our new data management platform, Discovery CORE, designed to share data in a privacy-preserving and secure manner across a network of collaborators, fostering and facilitating knowledge network building, vendor-neutral collaborative data analysis & management, education, training and teleophthalmology. Our Disease Evaluation Apps on Heidelberg Engineering’s secure data workflow solution, called AppWay, for connecting to AI applications.

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!